Business
Parsortix harvests cancer cells from bone marrow
Parsortix harvests cancer cells from bone marrow.
About this update from Cellbxhealth Plc
[{"type":"text","content":"\n \nRNS Number : 2654U Angle PLC 23 October 2017 \n\n\n\n\n\nFor immediate release\n\n\n 23 October 2017\n\n\n\n\n \nANGLE plc (\"the Company\")\n \n RESEARCHERS DEVELOP PARSORTIXTM-BASED PROCESS TO EFFICIENTLY HARVEST CANCER CELLS FROM BONE MARROW\n \nReactivation of such dormant cells has been implicated in patients with cancer relapse\n \n \nANGLE plc (AIM:AGL OTCQX:ANPCY), a world-leading liquid biopsy company, today announces that the Center for Women's Health Tuebingen, Germany, has presented the first report on a successful establishment of a protocol for detecting disseminated tumour cells (DTCs) using cancer patient bone marrow with the ParsortixTM system. \n \nThe reactivation of dormant DTCs and their release into the bloodstream as circulating tumour cells (CTCs), is the process by which a patient may, sometimes after many years of remission, suffer a relapse through metastasis. There is intense interest in the existence and status of such DTCs that are \"hibernating\" in the bone marrow.\n \nAt present, the method of choice for detecting DTCs is a density gradient centrifugation of the bone marrow to enrich for mononuclear cells and then an antibody-based staining for various cell markers. In experiments with spiked cancer cells this procedure was shown to be accompanied by a tremendous reduction of target cells with an average of up to 80% cell loss. This may well be one reason why, in primary breast cancer, DTCs have been found in the bone marrow of only 20-30% of patients.\n \nThe Tuebingen researchers have shown that their newly established ParsortixTM based protocol allows a recovery of about 80% of input target cells. Furthermore, the Tuebingen team believe that this easy to use method may well be applicable to other (non-blood) body fluids for detection of tumor cells for liquid biopsies.\n \nThe University Hospital Tuebingen research results were presented in a poster at Europe's leading CTC conference, the Third International Advances in Circulating Tumour Cells (ACTC) Symposium. A copy of the poster is available at https://angleplc.com/library/publications/. \n \nANGLE Founder and Chief Executive, Andrew Newland, commented:\n\"The presence of disseminated tumour cells (DTCs) in bone marrow has been shown in multiple studies to b...